742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

• David Hong,
• Manish Sharma,
• Erminia Massarelli,
• Heather Kinkead,
• Naomi B Haas,
• Rachel E Sanborn,
• Ralph J Hauke,
• Anthony W Tolcher,
• Neal Akhave,
• Jong Chul Park,
• Jennifer Carlisle,
• John Hamm,
• Alexander I Spira,
• David Berz,
• Vasily Andrianov,
• Brianne O’Neill,
• Justin A Call,
• Frank Yung-Chin Tsai,
• D Ross Camidge

Affiliations

David Hong

5The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Manish Sharma

3START Midwest, Grand Rapids, MI, USA

Erminia Massarelli

7City of Hope, Duarte, CA, USA

Heather Kinkead

Aff1 grid.21107.350000000121719311OncologyJohns Hopkins University Baltimore MD USA

Naomi B Haas

12Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Rachel E Sanborn

1Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA

Ralph J Hauke

6Nebraska Cancer Specialists, Omaha, NE, USA

Anthony W Tolcher

13NEXT Oncology, San Antonio, TX, USA

Neal Akhave

8The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Jong Chul Park

10 Massachusetts General Hospital, Boston, Massachusetts, USA

Jennifer Carlisle

Emory University, Decatur, GA, USA

John Hamm

11Norton Healthcare, Louisville, KY, USA

Alexander I Spira

5Virginia Cancer Specialists, Fairfax, VA, USA

David Berz

5Valkyrie Clinical Trials, Los Angeles, CA, USA

Vasily Andrianov

12Inhibrx, Inc, La Jolla, CA, USA

Brianne O’Neill

16Inhibrx, Inc, La Jolla, CA, USA

Justin A Call

20START Mountain Region, West Valley City, UT, USA

Frank Yung-Chin Tsai

7HonorHealth, Scottsdale, AZ, USA

D Ross Camidge

14University of Colorado Cancer Center, Aurora, CO, USA